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Abstract 
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) has gradually emerged and is one of the serious 
public health concerns worldwide. Aim: To detect Carbapenem Resistance in clinical isolates of Enterobacteriaceae 
and Carbapenamase production by performing Modified Hodge Test (MHT) and Combined Disc Test (CDT). 
Material & Methods: Identification of Isolates was done by standard bacteriological techniques. The isolates were 
screened for carbapenem resistance by Kirby-bauer disc diffusion method using Ertapenem as per CLSI 
recommendation. Detection of carbapenemase production was done by Modified Hodge test and Combined Disc 
test. Result: A total of 931 clinical isolates of Enterobacteriaceace were obtained from various clinical samples. Out 
of which isolates of Escherichia coli were 295 (31.68%). All these isolates were screened for Carbapenem 
resistance..Out of 931 isolates, 710 (76.26%) isolates were carbapenem screen positive. Maximum carbapenem 
resistance was seen in Klebsiella pneumoniae, 307 (43.23 %). Out of 710 carbapenem resistant isolates, 567 
(79.85%) were carbapenemase producers.  Conclusion: Early detection, isolation and contact precaution for CRE 
patient will to prevent rapid dissemination of CRE infection. 
Keywords: Carbapenem resistance, Enterobacteriacae, Modified Hodge Test. 
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Introduction 
The emergence of Carbapenem-Resistant Entero 
bacteriaceae (CRE) has become a major health concern 
worldwide and a new challenge in the treatment of 
infectious diseases.  
__________________ 
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The Enterobacteriaceae are a large family of Gram-
negative bacteria that may cause several infectious 
diseases such as respiratory tract infection, urinary tract 
infection etc. Carbapenem has been the main treatment 
for severe infections associated with Entero 
bacteriaceae.[1] 
Carbapenem-resistant Enterobacteriaceae (CRE) are 
usually resistant to all β-lactam agents as well as most 
other classes of antimicrobial agents. The treatment 
options are very few for patients infected with CRE. 
Carbapenem resistance in Enterobacteriaceae occurs 
when an isolate acquires a carbapenemase or when an 
isolate produces an extended - spectrum cephalo-
sporinase, such as an Amp C-type β-lactamase.[2] 
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Carbapenem resistance in Enterobacteriaceae is mainly 
mediated by the production of carbapenemases, a form 
of β-lactamase that cleave the β-lactam ring, an 
essential component of β-lactam antibiotics such as 
cephalosporins and carbapenems.[1] 
The common mechanisms that are responsible for 
carbapenem resistance include changes in outer 
membrane proteins over expression of drug efflux 
pumps and carbapenem hydrolyzing enzymes.[3]
 
In addition, carbapenemase producers are usually 
associated with many other non–β-lactam resistance 
determinants, which give rise to multidrug- and 
pandrug-resistant isolates.[4]
 
The drug resistance genes are often carried on mobile 
genetic elements and hence can easily transmit from 
person to person often via the hands of healthcare 
personnel or via contaminated medical equipment. 
These genes confer high levels of resistance to 
Carbapenems and many other antimicrobials 
(fluoroquinolones and aminoglycosides), often leaving 
very limited therapeutic options.[5] 
The majority of organisms in human gut flora are from 
Enterobactericeae family.[6] The prevention of spread 
of carbapenemase producers relies on early their 
detection ..Therefore, this study was carried out to 
detect carbapenem resistance in clinical isolates of 
Enterobacteriaceae in our hospital and to evaluate a 
simple, rapid cost effective method for detection of 
carbapenamase production. 
  
 
Material and Methods 
 
The present study was carried out in the Post Graduate 
Department of Microbiology, Subharti Medical 
College and associated Chhatarpati Shivaji Subharti 
Hospital (CSSH), Meerut. The study included all the 
clinical samples received in clinical Microbiology 
laboratory for Culture and Sensitivity from various 
inpatient units (ICUs & wards) and Out Patient 
Departments. Isolates were identified by standard 
bacteriological techniques.[7]
 
Antibiotic sensitivity was 
performed as per CLSI guidelines 2016.[8]
 
 
Screening of carbapenemase producers 
All the isolates were screened for carbapenem 
resistance using Ertapenem disc (10µg) by Kirby Bauer 
disc diffusion method according to CLSI guidelines.
  
 
Detection of carbapenemase production 
The MHT is a CLSI-recommended phenotypic method 
for carbapenemase detection.[8] 
 
MBL production was   
detected by performing CDT.[9]
 
 
Ethics  
Approval from Institutional Ethics Committee was 
obtained before conducting the study. 
 
 
 
 
 
Figure 1 : Modified Hodge Test positive: isolate showing a clover leaf like indentation (arrow) of the 
Escherichia coli 25922 growing along the test organism growth streak with the disc diffusion zone 
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Figure 2: Combined Disc Test positive: isolate showing an increase zone of diameter of ˃ 7 mm around the 
IPM-EDTA disc as compared o to that of IPM disc alone, indicating MBL producers 
 
Results 
A total of 931 clinical isolates of Enterobacteriaceace 
were obtained from various clinical samples. Out of 
which isolates of Escherichia coli were 295 (31.68%), 
Klebsiella pneumoniae ,279  (29.96%), Klebsiella 
oxytoca ,196 (21.05%), Citrobacter spp. ,89 (9.55%), 
Proteus spp. ,65 (6.98%) and Morganella morganii, 07 
(0.75%). All these isolates were screened for 
Carbapenem resistance.  
Out of 931 isolates, 710 (76.26%) isolates were 
carbapenem screen positive and 221 (23.7%) were 
carbapenem screen negative. Looking at the 
Distribution of carbapenem resistant isolates in IPD & 
OPD, it was found that majority were isolated from 
IPD patients 510/710 (71.83%) . 
Maximum carbapenem resistance was seen in 
Klebsiella pneumoniae, 307 (43.23 %) followed by 
Escherichia coli, 211 (29.71%), Klebsiella oxytoca, 
103 (14.50%), Citrobacter species, 53 (7.46%), Proteus 
spp. 30 (4.22%) and Morganella morganii 06 (0.84%). 
Looking at the sample wise distribution of Carbapenem 
resistant isolates, it was found that  urine, 220 (30.98 
%) was the predominant sample followed by pus ,157 
(22.11 %), sputum, 140 (19.71%), ET aspirate ,83 
(11.69%), blood ,54(7.60%), Stitch line swab ,19 
(2.67%), Central line tip, 14 (1.97%), Ascitic fluid, 
10(1.40%), ICD fluid, 08(1.12%) and  tissue 05 (0.70 
%). 
Out of 710 carbapenem resistant isolates, 567 (79.85%) 
were carbapenemase producers.  Only MHT was 
positive in 225/710 (31.69%) isolates.  Only CDT was 
positive in 196/710 (27.61%), both MHT & CDT were 
positive in 146/710 (20.56%), while both MHT & CDT 
were negative in 143/710 (20.14 %). (Table 1) 
 
 
 
 
 
Table 1 : Phenotypic characterization and distribution of Carbapenemase producers (n=710) 
ORGAN
ISM 
 
         
TEST 
Klebsiella 
pneumonia
e 
Escherichia 
coli 
Klebsiella 
oxytoca 
Citrobacter 
spp. 
Proteus 
spp. 
Morganella 
Morganii 
TOTAL/ % 
TOT
AL 
% TOT
AL 
% TOT
AL 
% TOT
AL 
% TOT
AL 
% TOT
AL 
% TOT
AL 
% 
Only 
MHT 
+ve 
75 24.
42 
80 37.
91 
35 33.
98 
19 35.
85 
13 43.
33 
03 50 225 31.
69 
Only 
CDT +ve 
74 24.
12 
72 34.
13 
26 25.
24 
14 26.
42 
09 30 01 16.
66 
196 27.
61 
BOTH 64 20. 48 22. 20 19. 10 18. 04 13. 00 00 146 20.
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MHT & 
CDT +ve 
84 74 41 86 33 56 
BOTH 
MHT & 
CDT –ve 
94 30.
61 
11 5.2
1 
22 21.
36 
10 18.
86 
04 13.
33 
02 33.
33 
143 20.
14 
TOTAL 
n=710 
307 100 211 100 103 100 53 100 30 100 06 100 710 100 
  
Discussion 
 
The study included a total of 931 isolates of 
Enterobacteriaceace from various clinical samples. Out 
of which, 710/931 (76.26%) isolates were carbapenem 
screen positive. Out of 710 carbapenem resistant 
isolates, 567/710 (79.85%) were carbapenemase 
producers ,which is much higher in comparison with 
the study done by Diwakar J et al in 2017 who reported 
carbapenem resistance in 43.4% isolates.[10] From 
India, numerous studies found different rates of 
carbapenem resistance, Akshaya R et al[5] in 2016 
reported carbapenem resistance in 13.95% isolates, 
Chauhan K et al in 2014[9] reported 20.72% (183/883) 
isolates were carbapenem screen positive which is 
much lesser than our finding. These findings suggest 
that carbapenem resistance is on the rise year by year 
indicating misuse and overuse of carbapenems. So, 
they should be used judiciously. 
 
In the present study MHT was positive in 225/710 
(31.69%) isolates.  Diwakar J et al in 2017 reported 
that 81.81% isolates were positive for carbapenemase 
production by modified Hodge Test.[10] In 2018 Gupta 
V et al
 
also reported 78% isolates of K. 
pneumoniae showed positive Modified 
Hodge Test (MHT).[11] Hence, screening should be 
done routinely in the laboratories for their early 
detection and initiation of appropriate therapy and 
appropriate measures can be taken to limit the spread 
of CRE. 
 
The authors found that CDT was positive in 196/710 
(27.61%) isolates. In 2018, Gupta V et al reported 
Metallo Beta Lactamase (MBL) production in 64% 
isolate by Combined Disc Test (CDT). [11]  Diwakar J 
et al in 2017 
 
  reported MBL production in 47.27% 
isolates by Meropenem with and without EDTA Ezy 
MIC™ Strips (Hi-Media) and combined disc test. [10] 
Chauhan K et al
  
 reported Carbapenemase production 
in 45.45% of E. coli and 38.67% of Klebsiella spp. 
using CDT.[9] The present study demonstrates the 
wide spread presence of MBLs in members of 
Enterobacteriaceae. Overall comparing the two 
phenotypic tests used for detection of carbapenamase 
production, it was observed that MHT could definitely 
detect more number of cases, 225/710 (31.69%)   as 
compared to CDT 196/710 (27.61%).    
 
 It is clearly seen in the present study that both MHT & 
CDT were positive in 146/710 (20.56%) isolates 
showing production of serine carbapenemases and 
MBLs. However, both MHT & CDT were negative in 
143/710 (20.14%). This negative result could be due to 
other important causes of carbapenem resistance 
among Enterobacteriaceae like porin loss etc.  
Maximum carbapenem resistance was seen in 
Klebsiella pneumoniae 307 (43.23 %) followed by 
Escherichia coli 211 (29.71%). Similarly, Diwakar et 
al in 2017 reported carbapenemase production 
predominantly in Klebsiella pneumoniae  (27.27%) 
strains followed by Escherichia coli (23.63%).[10] It 
might be due to the fact that predominant isolate in our 
study was Klebsiella pneumoniae   followed by 
Escherichia coli. 
 On analyzing the sample wise distribution of 
Carbapenem resistant isolates, it was found that   urine, 
220 (30.98 %) was the predominant sample followed 
by pus and other samples. This may be attributed to the 
fact that urine and pus were the most predominant 
samples received in our laboratory. Similar finding was 
reported by Diwakar et al who also found urine, 
26.36% to be the most predominant, followed by pus , 
Akshaya Rao et al  2016 also reported similar 
finding.[2] 
 
Conclusion 
The phenotypic assays, MHT and CDT have been 
suggested as gold standard techniques to detect 
carbapenemases and Metallo beta lactamases 
producing gram negative bacteria. To conclude, spread 
of carbapenamase is therapeautic threat. Thus, there is 
a need to identify correctly class A and class B 
carbapenamase producers. 
 
Limitation 
Molecular detection of genes responsible for 
Carbapenem resistance could not be done due to 
limited resources. 
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